These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7198457)

  • 61. Diisopropylfluorophosphate increases clofibric acid clearance: supporting evidence for a futile cycle.
    Rowe BJ; Meffin PJ
    J Pharmacol Exp Ther; 1984 Jul; 230(1):237-41. PubMed ID: 6747828
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Reduced clofibric acid clearance in renal dysfunction is due to a futile cycle.
    Meffin PJ; Zilm DM; Veenendaal JR
    J Pharmacol Exp Ther; 1983 Dec; 227(3):732-8. PubMed ID: 6655566
    [TBL] [Abstract][Full Text] [Related]  

  • 63. "In vitro" metabolism of bezafibrate by rat liver.
    Maffei FR; Carini M; Bertuletti R; Tofanetti O
    Pharmacol Res Commun; 1981 Feb; 13(2):121-32. PubMed ID: 7220572
    [No Abstract]   [Full Text] [Related]  

  • 64. [The pharmacokinetics of antilipemic agents. 5. Is 2-(4-hydroxyphenoxy)-2-methylpropionic acid a metabolite of the antilipemic ciprofibrate?].
    Oelschläger H; Rothley D; Hellwich KH; Schmidt W
    Arch Pharm (Weinheim); 1989 Jun; 322(6):337-42. PubMed ID: 2774869
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Oral and topical absorption, disposition kinetics, and the metabolic fate of trans-methyl styryl ketone in the male Fischer 344 rat.
    Sauer JM; Smith RL; Bao J; Kattnig MJ; Kuester RK; McClure TD; Mayersohn M; Sipes IG
    Drug Metab Dispos; 1997 Jun; 25(6):732-9. PubMed ID: 9193875
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Experimental pharmacological study of moroxybrate, a hypolipidaemic, antithrombotic, antiatheromatous agent.
    Moreau P; Jacotot B; Tillement JP
    J Pharm Pharmacol; 1987 Jan; 39(1):35-8. PubMed ID: 2880981
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure.
    Abshagen U; Kösters W; Kaufmann B; Lang PD
    Klin Wochenschr; 1980 Sep; 58(17):889-96. PubMed ID: 7442088
    [No Abstract]   [Full Text] [Related]  

  • 68. [Chemistry of phenoxyacetic acid esters of oxyalkyltheophyllines and 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methyl-propionate] (etofylline clofibrate), a novel antilipaemic agent (author's transl)].
    Metz G; Specker M
    Arzneimittelforschung; 1980; 30(11b):2014-9. PubMed ID: 7194051
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Experimental research on the action of a derivative from a p-chloropenoxyisobutyric acid series on lipid parameters].
    Filip M; Hriscu A; Păduraru I; Rusu M
    Rev Med Chir Soc Med Nat Iasi; 1986; 90(1):156-60. PubMed ID: 3764166
    [No Abstract]   [Full Text] [Related]  

  • 70. Species variation in the taurine conjugation of clofibric acid [proceedings].
    Caldwell J; Emudianughe TS; Smith RL
    Br J Pharmacol; 1979 Jul; 66(3):421P-422P. PubMed ID: 526711
    [No Abstract]   [Full Text] [Related]  

  • 71. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacokinetics and bioavailability of simfibrate a new clofibric acid derivative.
    Harvengt C; Desager JP
    Curr Ther Res Clin Exp; 1976 Jan; 19(1):145-151. PubMed ID: 812660
    [No Abstract]   [Full Text] [Related]  

  • 73. Effect of peroxisomes proliferators and hypolipemic agents on mitochondrial inner membrane linked D-3-hydroxybutyrate dehydrogenase (BDH).
    el Kebbaj MH; Cherkaoui Malki M; Latruffe N
    Biochem Mol Biol Int; 1995 Jan; 35(1):65-77. PubMed ID: 7735141
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacokinetics, protein binding and metabolic profile of 3H-icometasone enbutate following intravenous, oral and intratracheal administrations to Sprague-Dawley rats.
    Duchêne P; Giudicelli MD; Neau B; Gronfier A; Firmin Y; Villax P; Saivin S; Houin G
    Arzneimittelforschung; 1998 Apr; 48(4):371-8. PubMed ID: 9608879
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparative pharmacokinetics of 400 mg bezafibrate after a single oral administration of a new slow-release preparation and the currently available commercial form.
    Ledermann H; Kaufmann B
    J Int Med Res; 1981; 9(6):516-20. PubMed ID: 7319135
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dose-dependent pharmacokinetics of clofibric acid in the non-human primate.
    Walmsley LM
    Arch Toxicol Suppl; 1984; 7():272-7. PubMed ID: 6595991
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [An alternative in the therapy of primary hyperlipemias: etofibrate in depot preparations].
    Füsgen I; Summa JD
    Med Klin; 1980 Nov; 75(23):823-5. PubMed ID: 7442597
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers.
    Abshagen U; Spörl-Radun S; Marinow J
    Eur J Clin Pharmacol; 1980 Apr; 17(4):305-8. PubMed ID: 6995131
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Metabolism and pharmacokinetics of 1-(2'-trimethylacetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP117) in the rat.
    Choudhury R; Epemolu RO; Rai BL; Hider RC; Singh S
    Drug Metab Dispos; 1997 Mar; 25(3):332-9. PubMed ID: 9172951
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
    Altomonte L; Mingrone G; Ghirlanda G; Manna R; Rebuzzi A; Pala MA; Greco AV
    Minerva Med; 1980 Feb; 71(4):273-8. PubMed ID: 7354946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.